无锡药明康德新药开发股份有限公司 关于认购私募基金份额的公告

Investment Overview - The company, WuXi AppTec Healthcare Holding S.C.S.p, has signed a Subscription Agreement to invest €10 million (approximately ¥82.76 million) in the Jeito II S.L.P. private equity fund, representing 1.07% of the fund's total raised shares [2][4] - After the completion of the Subscription Agreement and Transfer Agreement, WuXi Lux Holding will hold a total of €30 million in A-class shares, accounting for approximately 3.22% of the total raised fund [3][8] - This investment does not require approval from the company's board of directors or shareholders and does not constitute a related party transaction or a major asset restructuring as defined by regulations [2][3] Fund Management and Structure - The investment fund is established under French law, targeting innovative companies in the biopharmaceutical sector with significant clinical needs and commercialization potential [8][15] - The fund's total size is capped at €1.2 billion, with approximately €931 million raised to date [8] - The fund's management team, Jeito Capital S.A.S., is noted for its professional investment management capabilities and compliance with local laws [4][6] Investment Strategy and Goals - The fund aims to invest in 14 to 17 early-stage medical innovation startups, focusing on biopharmaceutical companies [15][16] - The expected return model is based on asset appreciation after deducting management fees [16] - The fund will enter a liquidation phase at the end of its term, with a structured process for asset realization and distribution to investors [17] Impact on the Company - The investment is expected to enhance the company's understanding of developments in the European biopharmaceutical sector, which is a key potential customer base [19] - The company believes that the management team's experience and resources will provide critical growth capital and operational guidance to European biopharmaceutical startups [19] - The investment will not significantly impact the company's financial status or operational results, as it is made with the company's own funds while ensuring sufficient capital for daily operations [19]